Prosecution Insights
Prosecution Insights
13 pending office actions • 2 clients • 13 examiners • 9 art units • 0 of 13 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 13 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 13 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (8%) |
| §103 only | 4 (31%) |
| §102 only | 1 (8%) |
| No statute on record | 7 (54%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOAKES, SUZANNE MARIE | 1 | 73.1% | +18.3% |
| HADDAD, MAHER M | 1 | 50.4% | +54.3% |
| FAUST, AMBER KATHLEEN | 1 | 62.3% | +50.3% |
| LEONARD, ARTHUR S | 1 | 50.5% | +50.7% |
| COFFA, SERGIO | 1 | 61.0% | +33.3% |
| D' AMBROSIO, THEA | 1 | 55.6% | +56.8% |
| BOWERS, ERIN M | 1 | 54.9% | +11.4% |
| KIM, YUNSOO | 1 | 65.6% | +35.2% |
| GAO, ASHLEY HARTMAN | 1 | 59.8% | +38.9% |
| RAGHU, GANAPATHIRAM | 1 | 73.7% | +26.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18217401 | Sialylated Glycoproteins | LEONARD, ARTHUR S | 4d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18022069 | SIALYLATED GLYCOPROTEINS | KIM, YUNSOO | 52d overdue |
| 18218996 | Sialylated Glycoproteins | HADDAD, MAHER M | 36d overdue |
| 18218535 | Sialylated Glycoproteins | FAUST, AMBER KATHLEEN | 19d overdue |
| 18217401 | Sialylated Glycoproteins | LEONARD, ARTHUR S | 4d overdue |
| 18022061 | HYPERSIALYLATED IMMUNOGLOBULIN | BOWERS, ERIN M | 8d |
| 17925999 | HYPER-SIALYLATED IMMUNOGLOBULIN | GAO, ASHLEY HARTMAN | 15d |
| 17909282 | METHODS OF MAKING HYPER-SIALYLATED IMMUNOGLOBULIN | RAGHU, GANAPATHIRAM | 23d |
| 18136803 | Sialylated Glycoproteins | D' AMBROSIO, THEA | 27d |
| Client (Assignee) | Pending OAs |
|---|---|
| Johnson & Johnson | 8 |
| Takeda | 5 |
| Art Unit | Apps |
|---|---|
| 1654 | 3 |
| 1641 | 2 |
| 1658 | 2 |
| 1656 | 1 |
| 1643 | 1 |
| 1631 | 1 |
| 1653 | 1 |
| 1678 | 1 |
| 1652 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18545528 | REMOVAL OF SERINE PROTEASES BY TREATMENT WITH FINELY DIVIDED SILICON DIOXIDE | Takeda Pharmaceutical Company Limited | NOAKES, SUZANNE MARIE | 1656 | §102 | Final Rejection | 75d | Pending | Dec 19, 2023 |
| 18218996 | Sialylated Glycoproteins | Momenta Pharmaceuticals, Inc. | HADDAD, MAHER M | 1641 | Other | Non-Final OA | 36d overdue | Pending | Jul 06, 2023 |
| 18218535 | Sialylated Glycoproteins | Momenta Pharmaceuticals, Inc. | FAUST, AMBER KATHLEEN | 1643 | Other | Non-Final OA | 19d overdue | Pending | Jul 05, 2023 |
| 18217401 | Sialylated Glycoproteins | Momenta Pharmaceuticals, Inc. | LEONARD, ARTHUR S | 1631 | §101 | Non-Final OA | 4d overdue | Pending | Jun 30, 2023 |
| 18316988 | TREATMENT OF PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING ELECTIVE SURGERY BY ADMINISTRATION OF RECOMBINANT VWF | Takeda Pharmaceutical Company Limited | COFFA, SERGIO | 1658 | Other | Final Rejection | 55d | Pending | May 12, 2023 |
| 18136803 | Sialylated Glycoproteins | Momenta Pharmaceuticals, Inc. | D' AMBROSIO, THEA | 1654 | Other | Final Rejection | 27d | Pending | Apr 19, 2023 |
| 18022061 | HYPERSIALYLATED IMMUNOGLOBULIN | Momenta Pharmaceuticals, Inc. | BOWERS, ERIN M | 1653 | Other | Non-Final OA | 8d | Pending | Feb 17, 2023 |
| 18022069 | SIALYLATED GLYCOPROTEINS | Momenta Pharmaceuticals, Inc. | KIM, YUNSOO | 1641 | Other | Non-Final OA | 52d overdue | Pending | Feb 17, 2023 |
| 17925999 | HYPER-SIALYLATED IMMUNOGLOBULIN | Momenta Pharmaceuticals, Inc. | GAO, ASHLEY HARTMAN | 1678 | §103 | Final Rejection | 15d | Pending | Nov 17, 2022 |
| 17909282 | METHODS OF MAKING HYPER-SIALYLATED IMMUNOGLOBULIN | Momenta Pharmaceuticals, Inc. | RAGHU, GANAPATHIRAM | 1652 | §103 | Final Rejection | 23d | Pending | Sep 02, 2022 |
| 17556857 | PURIFICATION OF FVIII FROM PLASMA USING SILICON OXIDE ADSORPTION | Takeda Pharmaceutical Company Limited | ESPINOSA, CLAUDIA EDILMA | 1654 | §103 | Non-Final OA | 66d overdue | Pending | Dec 20, 2021 |
| 17362191 | METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF) | Takeda Pharmaceutical Company Limited | AUDET, MAURY A | 1654 | §103 | Final Rejection | 79d | Pending | Jun 29, 2021 |
| 17169835 | SEPARATION OF VWF AND VWF PROPEPTIDE BY CHROMATOGRAPHIC METHODS | Takeda Pharmaceutical Company Limited | STEELE, AMBER D | 1658 | Other | Non-Final OA | 89d overdue | Pending | Feb 08, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial